Actovegin in the management of patients after ischemic stroke: A systematic review.
Review of earlier studies · 2022
- What was studied
- Five controlled studies after ischemic stroke; one randomized trial and four observational studies
- Main finding
- The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
Study data at a glance
- Participants or experimental model
- Five controlled studies after ischemic stroke; one randomized trial and four observational studies
- Reported results
- The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
Study limitations and source details
Study limitations
- Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.
Source details
Journal publication
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Sources checked
Citation
la Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D. Actovegin in the management of patients after ischemic stroke: A systematic review. PloS one
Study source ↗ · DOI 10.1371/journal.pone.0270497 · Bibliography entry · Link to this summary